US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Supernus Pharmaceuticals, Inc. - Common Stock
(NQ:
SUPN
)
42.38
+0.20 (+0.47%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Supernus Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
3 of Wall Street’s Favorite Stocks We Approach with Caution
June 19, 2026
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Via
StockStory
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead
June 16, 2026
Over the last six months, Supernus Pharmaceuticals’s shares have sunk to $43.79, producing a disappointing 9.4% loss - a stark contrast to the S&P 500’s 9.3%...
Via
StockStory
Topics
Stocks
Supply Chain
1 Cash-Heavy Stock on Our Watchlist and 2 Facing Challenges
June 05, 2026
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...
Via
StockStory
Supernus Pharmaceuticals to Participate in June Investor Conferences
May 27, 2026
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Q1 Estimates as Growth Products Drive 39% Revenue Surge
↗
May 05, 2026
Via
Chartmill
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Posts Strong Q4 Beat as CNS Portfolio Accelerates Growth
↗
February 24, 2026
Via
Chartmill
3 Stocks Under $50 with Open Questions
May 21, 2026
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...
Via
StockStory
3 Small-Cap Stocks That Concern Us
May 18, 2026
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Via
StockStory
Topics
Artificial Intelligence
3 Growth Stocks We Approach with Caution
May 15, 2026
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...
Via
StockStory
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year
↗
May 12, 2026
Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare providers and specialty pharmacies nationwide.
Via
The Motley Fool
Topics
Regulatory Compliance
5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings Call
May 12, 2026
Supernus Pharmaceuticals’ first quarter saw a positive market response, as management attributed the revenue growth to robust demand for its key growth produ...
Via
StockStory
Topics
Earnings
Supply Chain
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today
May 07, 2026
What Happened? Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 6.8% in the afternoon session after the company repor...
Via
StockStory
Topics
Earnings
Economy
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
May 06, 2026
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
SUPN Q1 Deep Dive: Growth Products Drive Revenue Upside, Guidance Highlights Execution Challenges
May 06, 2026
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 38.6% year on yea...
Via
StockStory
Topics
Economy
Supply Chain
1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges
May 06, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged...
Via
StockStory
Supernus (SUPN) Q1 2026 Earnings Transcript
↗
May 05, 2026
Supernus (SUPN) Q1 2026 Earnings Transcript
Via
The Motley Fool
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 CY2026 Sales Beat Estimates
May 05, 2026
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 38.6...
Via
StockStory
Topics
Earnings
Supernus Announces First Quarter 2026 Financial Results
May 05, 2026
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
May 03, 2026
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results this Tuesday after the bell. Here’s what to look ...
Via
StockStory
Topics
Artificial Intelligence
Branded Pharmaceuticals Stocks Q4 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
April 26, 2026
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
April 22, 2026
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know
April 17, 2026
What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...
Via
StockStory
Topics
Economy
3 Unprofitable Stocks We Think Twice About
April 14, 2026
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...
Via
StockStory
1 Cash-Producing Stock to Consider Right Now and 2 Facing Headwinds
April 13, 2026
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas...
Via
StockStory
Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year
↗
March 27, 2026
Specializing in CNS therapies, this biopharma firm reported a notable insider sale amid a year of strong stock performance.
Via
The Motley Fool
Topics
Regulatory Compliance
3 Reasons SUPN is Risky and 1 Stock to Buy Instead
March 12, 2026
Supernus Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.1%. The stock now trades at $53.23, m...
Via
StockStory
Topics
Stocks
Supply Chain
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q4 CY2025: Strong Sales
February 24, 2026
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 21.5% year on year to $211.6 million. On the...
Via
StockStory
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
February 24, 2026
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Participate in March Investor Conferences
February 23, 2026
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect
February 22, 2026
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results this Tuesday after market hours. Here’s what investors should know.
Via
StockStory
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
